Hematology-Oncology
Mitigating CD8 T-cell Exhaustion to Overcome CAR T-cell Therapy Failure in Large B-cell Lymphoma
This article reviews how non-alpha IL2 receptor agonist pegenzileukin can counteract CD8 T-cell exhaustion, a key mechanism in CAR T-cell (CART19) therapy failure in relapsed/refractory large B-cell lymphoma, enhancing therapeutic efficacy
